oral semaglutide cardiovascular benefit Outcomes, Safety, and Tolerability With Semaglutide: Insights for Managed Care PIONEER 6: Oral Semaglutide Passes

Accessed on August 15, 2025.

The findings align with growing clinical evidence that GLP-1 therapy positively affects cardiometabolic risk factors, including blood pressure, blood sugar, and lipid profiles, even in complex patient populations

Considerations There may be some side effects in the initial period

Its going to be a larger overall cost, a cost to the system.

By identifying patients at risk for side effects before treatment begins, we can match the right patient to the right therapy, increase real-world adherence, and dramatically improve clinical trial efficiency through smarter patient selection

If you have a lapse in taking your medication, talk to your care provider